SUMMARY FINANCIAL DATA
|
|
- Silvester Pearson
- 5 years ago
- Views:
Transcription
1 Company Initiation (28513) Vaccines set to go global We reinstate coverage of at BUY with a KRW1, target. The company will likely benefit from its recent co-polyester plant capacity additions and subsequent utilization hikes, with it also poised to gain earnings momentum from: 1) the release of new products by its life science business; 2) royalty income for CSL s hemophilia A treatment Afstyla; and 3) development milestones from Sanofi which should start Phase I clinical trials overseas for diplococcus pneumoniae vaccine in 1H19. Keunhee Seo, Ph.D. Analyst keunhee.seo@samsung.com Wonyong Park, CFA Analyst wkrw.park@samsung.com AT A GLANCE Target price KRW1, (38.9%) Current price KRW72, Market cap KRW833.75b/USD736.92m Shares (float) 11,579,852 (63.5%) 52-week high/low Avg daily trading value (6-day) KRW122,/KRW72, KRW3.9b/ USD3.5m ONE-YEAR PERFORMANCE 1M 6M 12M (%) Vs Kospi (%pts) SAMSUNG vs THE STREET No of estimates 2 Target price 13, Recommendation 4. BUY : 5 / BUY: 4 / HOLD: 3 / SELL: 2 / SELL : 1 WHAT S THE STORY? Near-term earnings stagnant, but long-term growth drivers in place: We reinstate coverage of (SKC) at BUY with a 12-month target price of KRW1,, on expectations of its: 1) green chemicals division enjoying operating leverage amid growing demand for co-polyester; and 2) life science division posting steady growth with it set to debut several vaccines. The firm has an estimated enterprise value of KRW1.16t, which is based on a DCF valuation given the prospects of all-round growth and steady rises in free cash flows. Increased costs from strong oil prices could hit its near-term valuation, along with steady losses by consolidated subsidiary Initz, but SKC s enterprise value ought to rise grow steadily amid expansion of the vaccine business. Green chemicals division to boost sales and cut costs: The green chemical division of SKC added co-polyester production capacity of 6, tonnes last year to its 12, tonnes of polyester production capacity, with both plants fully up and running amid strong demand, so more capacity expansions are planned. The division should enjoy sales growth since Korea raised its mandatory biodiesel blend ratio from 2.5% in 217 to 3% this year, but earnings growth might be limited as strong oil prices subsequently lift those for raw materials PTA and MEG. We expect the division s full-year sales and operating profit to rise a respective 15.2% and 11.2% to KRW1t and KRW51.6b. Life science division poised for full-fledged growth: SKC s life science division and vaccine business benefit from stable influenza vaccine sales, market-share gains from proprietary herpes zoster vaccine SKYzoster, royalty income for CSL s hemophilia A treatment Afstyla, and out-licensing deals with Sanofi Pasteur. Its sales and operating profit will likely climb 14.8% and 169.9% to KRW368.7b and KRW28.3b this year. SUMMARY FINANCIAL DATA (Continued on the next page) E 219E 22E Revenue (KRWb) 88 1,426 1,516 1,582 Net profit (adj) (KRWb) (1) EPS (adj) (KRW) (655) 3,226 4,37 6,886 EPS (adj) growth (% y-y) nm nm EBITDA margin (%) (2.) ROE (%) (1.2) P/E (adj) (x) n/a P/B (x) EV/EBITDA (x) n/a Dividend yield (%).... Source: Company data, Samsung Securities estimates
2 Vaccines set to go global: We foresee enjoying influenza vaccine sales growth at home before starting related exports from 22 after winning WHO pre-qualification, with exports of varicella vaccine set to commence next year with it expected to win a Pan American Health Organization bid. SKC should receive royalties of KRW4b this year from out-licensing Afstyla to CSL in addition to KRW16b from an out-licensing contract with Sanofi Pasteur (France). It also expected to recognize development milestones from diplococcus pneumoniae vaccine (out-licensed to Sanofi) as the treatment is scheduled to enter US Phase I clinical trials in 1H19. 91
3 Valuation We reinstate coverage of SKC at BUY with a 12-month target price of KRW1,, which we derived from a discounted cash flow (DCF) valuation to reflect its: 1) increased utilization to fulfil copolyester demand growth; and 2) upcoming release of several vaccines that should bring stable earnings growth at the life science division. Our major assumptions include a risk-free rate of 2% (based on yields on 3-year treasury bonds), market risk premium of 7.57%, a 52-week average beta of.7x, and perpetual growth rate of 1.9% (Korea s projected GDP growth rate in 22). Our initial target price has 34.7% upside at current prices. We use a [supplementary] sum-of-the-parts valuation method that also begets a fair value of KRW1,, which is calculated by subtracting SKC s net debt of KRW776.5b from the sum of its operating value ie, KRW1.363t, comprising the green chemicals division (KRW712.5b, based on the 7x forward EV/EBITDA of major pharmaceuticals players), and the life science division (KRW651.2b, based on the 13.2x average EV/EBITDA of large domestic pharmaceuticals) and non-operating value of KRW485.8b (comprising KRW23.7b from pipeline drugs and KRW166.3b from other invested assets). DCF valuation (KRWb) 218E 219E 22E 221E 222E 223E 224E 225E Green Chemical Division 1,2 1,99 1,131 1,2 1,39 1,61 1,82 1,1 Y-y (%) (9.8) Life Science Division Y-y (%) Others Y-y (%) (64.7) Sales 1,426 1,516 1,582 1,756 1,91 2,45 2,16 2,257 Y-y (%) EBIT Tax rate (%) NOPLAT Depreciation CAPEX Change in working capital FCF (65) (78) (47) WACC (%) 5.7 Permanent growth rate (%) 1.9 Permanent value 2,814 Discount rate (%) Present value of FCF (61) (7) (4) Present value of permanent value 1,81 Total present value 1,937 Net borrowings 777 Fair value 1,16 Adjusted number of outstanding shares ( ) 11,58 Target price, unrounded (KRW) 1,175 Target price (KRW) 1, Current price (KRW) 72, Upsides (%) 38.9 Notes: Cost of equity = 7.4%, based on risk-free rate of 2% (ie, 3-year KTB yield), market risk premium of 7.57%, and 52-week beta of.7 Permanent growth rate = 1.9%, equal to consensus estimate of Korea s GDP growth rate Source: Samsung Securities estimates 92
4 SOTP valuation (KRWb) Forward EBITDA EV/EBITDA Note A. Operating value (B+C) 1,364 B. Green Chemical Division Kospi Chemistry Sector forward EV/EBITDA Kospi Pharmaceuticals Sector forward C. Life Science Division EV/EBITDA D. Non-operating value (E+F+J) 486 E. New drugs 231 Royalties from Afstyla F. Investment equities (G+H+I) 166 Book value G. SK Petrochemical (1%) 29 H. Initz (66%) 69 I. Other 68 J. Real estate investments 89 Book value K. Net borrowings 777 L. Target value (A+D-K) 1,162 M. Adjusted number of outstanding shares ( ) 11,58 N. Per-share fair value (L/M)(KRW) 1,335 O. Target price (KRW) 1, P. Current price (KRW) 72, Q. Upside (%) 38.9 Source Company data, Samsung Securities estimates 93
5 Earnings estimates 218 results being driven by life science division Our forecasts have the 218 sales and operating of SKC up a respective 6% and 125.1% to KRW1.426t and KRW51.3b, with those of its: 1) green chemicals division expected to rise 15.2% and 11.2%, respectively, to KRW1t and KRW51.6b thanks to Korea s mandatory biodiesel blend ratio being raised from 2.5% in 217 to 3% this year, which boosted utilization rates of its new co-polyester plant; and 2) life science division to jump a respective 14.8% and 169.9% to KRW368.7b and KRW28.3b on stable sales of influenza vaccines, the debut of proprietary herpes zoster vaccine SKYzoster, and royalty income hikes for CSL s hemophilia A treatment Afstyla. We expect the parent s sales and operating profit to grow 6.3% and 42.2% to a respective KRW1.515t and KRW73b next year, thanks to: 1) reduced losses by consolidated subsidiary Initz; 2) leverage effects as its green chemicals division increases utilization; and 3) stable earnings growth at its life science division. Sales outlook, by segment (KRW 1 million) 5, 4, 3, 2, 1, 975 1, ,16 1,16 1, , ,57 1,11 1,14 1,38 1,12 1,13 1,56 1,232 1, Q17 2Q17 3Q17 4Q17 1Q18 2Q18 3Q18E 4Q18E 1Q19E 2Q19E 3Q19E 4Q19E Life Science Co-polyester Bioenergy Others Source Company data, Samsung Securities estimates Operating profit outlook, by segment (KRW 1 million) (7) (4) (1) (1) (17) (48) (39) (33) (5) (3) (38) (8) (8) (63) (2) (3) (4) 1Q17 2Q17 3Q17 4Q17 1Q18 2Q18 3Q18E 4Q18E 1Q19E 2Q19E 3Q19E 4Q19E Life Science Co-polyester Bioenergy Others Source Company data, Samsung Securities estimates 94
6 217 h 219E 3Q 17-2Q18 P/E band P/B band (KRW) (KRW) 16, 14, 12, 1, 8, 6, 35x 3x 25x 2x 15x 16, 14, 12, 1, 8, 6, 2.2x 1.9x 1.6x 1.3x 1.x 4, 4, 2, Jan 18 Apr 18 Jul 18 Oct 18 2, Jan 18 Apr 18 Jul 18 Oct 18 Source: QuantiWise, Samsung Securities Source: QuantiWise, Samsung Securities Ownership structure Choi Chang-won et al. 44.6% SK Discovery 24.8% 28.3% 45.6% SK E&C SK Gas Source: Company data, Samsung Securities : Shareholding structure SK Discovery: Shareholding structure Others 64.3% SK Discovery 24.8% NPS 1.9% Others 48.2% Choi Chang-won et al. 44.6% Source: Company data, Samsung Securities Source: Company data, Samsung Securities NPS 7.2% 95
7 Income statement Year-end Dec 31(KRWb) E 219E 22E Sales n/a 88 1,426 1,516 1,582 Cost of goods sold n/a 75 1,133 1,21 1,25 Gross profit n/a Gross margin (%) n/a SG&A expenses n/a Operating profit n/a (9) Operating margin (%) n/a (1.5) Non-operating gains (losses) n/a (3) (28) (23) (2) Financial profit Financial costs Equity-method gains (losses) () Other n/a (1) (6) (5) (5) Pre-tax profit n/a (13) Taxes n/a (3) (3) 1 16 Effective tax rate (%) n/a 21.5 (14.) Profit from continuing operations (1) Profit from discontinued operations Net profit n/a (1) Net margin (%) n/a (11.3) Net profit (controlling interests) n/a (9) Net profit (non-controlling interests) n/a (1) (15) (16) (26) EBITDA n/a (2) EBITDA margin (%) n/a (2.) EPS (parent-based) (KRW) n/a (655) 3,226 4,37 6,886 EPS (consolidated) (KRW) n/a (758) 2,47 3,76 4,919 Adjusted EPS (KRW)* n/a (655) 3,226 4,37 6,886 Balance sheet Year-end Dec 31(KRWb) E 219E 22E Current assets n/a Cash & equivalents n/a Accounts receivable n/a Inventories n/a Other current assets n/a Fixed assets n/a 1,25 1,253 1,246 1,249 Investment assets n/a Tangible assets n/a 1,98 1,11 1,97 1,13 Intangible assets n/a Other long-term assets n/a Total assets n/a 1,912 2,19 2,157 2,233 Current liabilities n/a Accounts payable n/a Short-term debt n/a Other current liabilities n/a Long-term liabilities n/a Bonds & long-term debt Other long-term liabilities n/a Total liabilities n/a 1,181 1,35 1,359 1,37 Owners of parent equity n/a Capital stock n/a Capital surplus n/a Retained earnings n/a (9) Other n/a (27) (33) (33) (33) Non-controlling interests equity n/a (14) Total equity n/a Net debt n/a Cash flow statement Year-end Dec 31(KRWb) E 219E 22E Cash flow from operations (11) Net profit (1) Non-cash profit and expenses Depreciation Amortization Other Changes in A/L from operating activities (1) (57) (9) (12) Cash flow from investments (9) (86) (73) (76) Change in tangible assets (8) (79) (72) (75) Change in financial assets (15) 4 () (1) Other 15 (1) (1) (1) Cash flow from financing Change in debt Change in equity 733 (3) Dividends n/a Other n/a (1,614) (12) Change in cash (11) Cash at beginning of year Cash at end of year Gross cash flow Free cash flow (19) (28) Note: * Excluding one off items ** Fully diluted, excluding one-off items *** From companies subject to equity-method valuation Source: Company data, Samsung Securities estimates Financial ratios Year-end Dec E 219E 22E Growth (%) Sales nm nm 1, Operating profit nm nm nm Net profit nm nm nm Adjusted EPS** nm nm nm Per-share data (KRW) EPS (parent-based) n/a (655) 3,226 4,37 6,886 EPS (consolidated) n/a (758) 2,47 3,76 4,919 Adjusted EPS** n/a (655) 3,226 4,37 6,886 BVPS n/a 53,425 56,53 6,364 67,257 DPS (common) Valuations (x) P/E*** n/a n/a P/B*** n/a EV/EBITDA n/a n/a Ratios (%) ROE n/a (1.2) ROA n/a (.5) ROIC n/a (.5) Payout ratio n/a.... Dividend yield (common)..... Net debt to equity n/a Interest coverage (x) n/a (4.)
LG International (001120) Poor 3Q expected to be just a blip WHAT S THE STORY? SUMMARY OF 3Q RESULTS
Company Update LG International (112) Poor 3Q expected to be just a blip Jaeseung Baek Analyst jaeseung.baek@samsung.com 822 22 7794 LG International (LGI) yesterday reported that its consolidated sales
More informationSimmtech (222800) Focus on 2H earnings WHAT S THE STORY?
Company Update Simmtech (222800) Focus on 2H earnings Simmtech yesterday reported disappointing 4Q results, which compels us to cut our 2018 operating profit forecast by 10% to KRW52.9b and 12-month target
More informationDaewoo E&C ( KS) WHAT S THE STORY?
Company Update (047040 KS) All-round margin improvements WHAT S THE STORY? Event: yesterday after market close reported that its parentbased operating profit hit KRW107.6b in 3Q, vs the consolidated consensus
More informationFila Korea (081660) Widespread growth potential
Fila Korea (8166) BUY (Maintain), TP: W98, (Maintain) Stock price (Apr 26, KRW) 83,5 Yr to Sales OP EBT NP EPS % chg EBITDA P/E EV/EBITDA P/B ROE Market cap (USD mn) 697 Dec (W bn) (W bn) (W bn) (W bn)
More informationYG Entertainment (122870)
Company Note August 29, 212 12M rating BUY (Maintain) 12M TP W69, from W69, Up/downside +11% Stock Data KOSPI (Aug 28, pt) 1,916 Stock price (Aug 28, KRW) 62,2 Market cap (USD mn) 561 Shares outstanding
More informationKorea Zinc (010130) Company Note. 1Q12 preview: Not over until it s over. BUY (Maintain)
Company Note April 1, 212 Korea Zinc (113) 12M rating BUY (Maintain) 12M TP W6, from W6, Up/downside +57% Stock Data KOSPI (Apr 9, pt) 1,997 Stock price (Apr 9, KRW) 381,5 Market cap (USD mn) 6,286 Shares
More informationWonik Materials (104830)
Company Note January 19, 2012 Wonik Materials (104830) 12M rating 12M TP Up/downside Stock Data NM NA NM KOSPI (Jan 18, pt) 1,892 Stock price (Jan 18, KRW) 37,350 Market cap (USD mn) 189 Shares outstanding
More informationDaewoong Pharmaceutical (069620)
Earnings Review July 31, 2014 12M rating BUY (Maintain) 12M TP W85,000 from W85,000 Up/downside +44% Stock Data KOSPI (Jul 30, pt) 2,083 Stock price (Jul 30, KRW) 58,900 Market cap (USD mn) 666 Shares
More informationTable 1. Sum-of-the-parts valuation. EPS Growth
(001120) Solid 4Q, excluding one-offs (LGI) yesterday reported that its consolidated sales rose 3.8% q-q to KRW3.8t in 4Q, but that its operating profit plunged 98% q-q to KRW600m with a net loss of KRW237.2b,
More informationYG Entertainment (122870)
Company Note February 23, 2017 YG Entertainment (122870) 12M rating Value Stock Data Hold (Downgrade) Growth Turn around Issue KOSPI (Feb 22, pt) 2,107 Stock price (Feb 22, KRW) 27,850 Market cap (USD
More informationMegastudy (072870/BUY )
(7287/BUY ) RESULTS NOTE 3Q numbers down y-y but in line with estimates Target price KRW2, Upside/downside +19.8% Current price KRW166,9 3Q earnings disappoint on weak high school online division performance
More informationDongsung Finetec (033500)
Earnings Review November 15, 213 12M rating BUY (Maintain) 12M TP W13, from W13, Dongsung Finetec (335) Full-bore turnaround Above In line Below Up/downside +2% Stock Data KOSPI (Nov 14, pt) 1,968 Stock
More informationLotte Confectionery (004990)
Company Note May 9, 211 Lotte Confectionery (499) BUY (Maintain) TP: W2,, (Up) KOSPI (May 6) 2,147 Stock price (May 6) 1,67, Shares outstanding (mn) 1.4 Market cap (USD mn) 2,19 52-Week Low/High (won)
More informationHalla Visteon Climate Control (018880)
Halla Visteon Climate Control (1888) Hold (Reinstate) Stock price (Mar 31, KRW) 48,6 Market cap (USD mn) 4,873 Shares outstanding (mn) 17 52W High/Low (KRW) 48,6/27,2 6M avg. daily turnover (USD mn) 6.8
More informationDuksan Hi-Metal (077360)
Company Note March 14, 2014 Duksan Hi-Metal (077360) 12M rating BUY (Maintain) 12M TP W24,000 from W24,000 Up/downside +32% Stock Data KOSPI (Mar 13, pt) 1,934 Stock price (Mar 13, KRW) 18,250 Market cap
More informationDong-A Pharmaceutical ( KS)
Dong-A Pharmaceutical (64 KS) Trading Buy (Initiate) Target Price (12M, W) 115, Share Price (9/3/12, W) 94,6 Expected Return (%) 21.6 EPS Growth (12F, %) -3.7 Market EPS Growth (12F, %) 12.7 P/E (12F,
More informationS-Oil (010950) Healthier revenue structure already reflected in valuations
S-Oil (010950) Hold (Initiate) Stock price (Sep 15, KRW) 46,000 Market cap (USD mn) 4,989 Shares outstanding (mn) 113 52W High/Low (KRW) 81,200/43,500 6M avg. daily turnover (USD mn) 15.4 Free float (%)
More informationLG Innotek (011070) Company Note. Concerns unjustified, 3Q14 results to beat consensus. BUY (Maintain)
Company Note August 29, 214 LG Innotek (117) 12M rating BUY (Maintain) 12M TP W17, from W17, Up/downside +29% Stock Data KOSPI (Aug 28, pt) 2,76 Stock price (Aug 28, KRW) 132, Market cap (USD mn) 3,22
More informationCrucialTec (114120) BUY (Maintain) Company Note. Robust growth to continue. TP: W70,000 (Up)
Company Note February 22, 2011 CrucialTec (114120) BUY (Maintain) TP: W70,000 (Up) KOSPI (Feb 21) 2,005 Stock price (Feb 21) 46,300 Shares outstanding (mn) 8.4 Market cap (USD mn) 349 52-Week Low/High
More informationPER EV/EBITDA PBR ROE
December 19, 213 (3671 KS) Focus on turnaround in 214 BUY (UPGRADE) Price (Dec. 18) W6,38 Target Price W8, % variance 25.4% YoungChan (82-2) 3772-1595 Kim youngkim@shinhan.com KOSPI 1,974.63p KOSDAQ 485.65p
More informationHyundai Steel (004020)
Earnings Review February 1, 213 12M rating BUY (Maintain) 12M TP W111, from W111, Hyundai Steel (42) Astonishing earnings in many aspects Above In line Below Up/downside +34% Stock Data KOSPI (Jan 31,
More informationP/E EV/EBITDA P/B ROE
FILA Korea (8166) BUY (Maintain), TP: W86, (Up) Stock price (Apr 4, KRW) 67,2 Market cap (USD mn) 594 Shares outstanding (mn) 1 52W High/Low (KRW) 89,9/57,5 6M avg. daily turnover (USD mn) 4.4 Free float
More informationDaewoo E&C (047040) Company Note. Asia conference feedback; Contrarian thinking
Company Note February 10, 2012 Daewoo E&C (047040) 12M rating BUY (Maintain) 12M TP W17,000 from W17,000 Up/downside +45% Stock Data KOSPI (Feb 8, pt) 2,004 Stock price (Feb 8, KRW) 11,750 Market cap (USD
More informationSimmtech ( KS)
Sep 7, 218 Electronics/parts DRAM upgrade begins 2H18 earnings likely to turn around strongly, with OP estimated at W31.5bn Rating Target price BUY (M) W21,6 (M) Current price (Sep 4) W9,51 Upside potential
More informationLG Innotek ( KS)
Company Report Apr 6, 215 LG Innotek (117 KS) With uncertainties priced in, time to shed light on positives Electronics/parts BUY (M) TP: W135, (M) Share price (won, Apr 3) 11,5 Paid-in capital (Wbn) 118
More informationCosmax (192820) Company Note. Smooth transition, third growth phase. BUY (Initiate)
Company Note April 7, 2014 (192820) 12M rating BUY (Initiate) 12M TP W75,000 Up/downside +23% Stock Data(Pre-separation data) KOSPI (Apr 4, pt) 1,988 Stock (Apr 4, KRW) 60,000 Market cap (USD mn) 774 Shares
More informationCheil Industries (028260)
Company Note May 27, 2015 Cheil Industries (028260) 12M rating BUY (Maintain) 12M TP W255,000 from W200,000 Up/downside +36% Stock Data KOSPI (May 26, pt) 2,144 Stock price (May 26, KRW) 188,000 Market
More informationWonik Materials (104830)
Company Note July 17, 213 Wonik Materials (1483) 12M rating BUY (Maintain) 12M TP W52, from W44, Up/downside +44% Stock Data KOSPI (Jul 16, pt) 1,866 Stock price (Jul 16, KRW) 36,1 Market cap (USD mn)
More informationSilicon Works (108320)
Company Note June 8, 2018 12M rating BUY (Maintain) OLED growth starts with Silicon Works 12M TP W56,000 Up/downside +38% from W56,000 2Q18 OP to surge 165% YoY to W8.4bn Despite disappointing 1Q18 results,
More informationLG International ( KS)
April 15, 214 (112 KS) Clearer visibility on long-term earnings growth BUY (MAINTAIN) Price (Apr. 14) W3,15 Target Price W38, % variance 26.% MinHo Hur (82-2) 3772-2183 hiroo79@shinhan.com KOSPI 1,997.2p
More informationVieworks (100120) Earnings Review. Competitiveness to sustain growth. BUY (Maintain)
Earnings Review August 21, 214 12M rating BUY (Maintain) 12M TP W39, from W34, Up/downside +27% Stock Data KOSPI (Aug 2, pt) 2,73 Stock price (Aug 2, KRW) 3,8 Market cap (USD mn) 38 Shares outstanding
More informationKorean Air (003490) Company Note. Timely relisting. Hold (Maintain)
Company Note September 16, 2013 12M rating Hold (Maintain) Timely relisting Stock Data KOSPI (Sep 13, pt) 1,994 Stock price (Sep 13, KRW) 28,200 Market cap (USD mn) 1,890 Shares outstanding (mn) 59 52-Week
More informationLotte Hi-Mart ( KS)
(071840 KS) Margins to improve in 2H Retail Results Comment May 12, 2014 (Maintain) Buy Target Price (12M, W) 89,000 Share Price (5/9/14, W) 72,300 Expected Return 23% OP (, Wbn) 187 Consensus OP (, Wbn)
More informationDaewoong Pharmaceutical ( KS)
June 11, 214 (6962 KS) Shares and earnings touch bottom BUY (UPGRADE) Price (Jun. 1) W58,8 Target Price W74, % variance 25.9% KiDal Bae (82-2) 3772-1554 kdbae@shinhan.com EungHyun Kim (82-2) 3772-1568
More informationPharmaceuticals & Biotech.
Sector Note July 14, 211 Overweight Company Rating TP (KRW) Green Cross BUY 215, Yuhan BUY 218, LG Life Sciences Hold 55, Daewoong Pharm. BUY 55, Hanmi Pharm Hold 98, Dong-A Pharm. BUY 151, Pharmaceuticals
More informationSilicon Works ( KS)
January 18, 217 (1832 KS) 4Q16 preview: Better than expected BUY (MAINTAIN) Price (Jan. 17) W3,4 Target Price W36, % variance 2.% YoungSik Yoon (82-2) 3772-153 youngsik.yoon@shinhan.com JoonDoo Ha (82-2)
More informationHankook Tire ( KS)
June 11, 214 (16139 KS) Global top 3 for profitability BUY (MAINTAIN) Price (Jun. 1) W64,2 Target Price W78, % variance 21.5% Eric Choi (82-2) 3772-1552 eric.choi@shinhan.com KOSPI 2,11.8p KOSDAQ 532.64p
More informationTOFAS. Company Update. Still offers potential value BUY. Rating. 19 February 2019
Feb-18 Mar-18 Apr-18 May-18 Jun-18 Jul-18 Aug-18 Sep-18 Oct-18 Nov-18 Dec-18 Jan-19 Company Update TOFAS Still offers potential value Tofas has been a laggard in the last one-year period, due to weaker
More informationHankook Tire ( KS)
(16139 KS) Aggressive expansion to enhance global presence Auto Results Comment October 29, 213 (Maintain) Buy Target Price (12M, W) 78, Share Price (1/28/13, W) 65,4 Expected Return 19% OP (13F, Wbn)
More informationDubai Financial Market
June 21, 2009 Fair Value Estimate: AED 2.04 Recommendation:: Hold Executive Summary DFM posted a weak operating result in Q1 2009. Total revenue fell 24.7% q-o-q to AED 68.6mn due to lower trading commission
More informationKolon Industries (120110)
KOREA November 25, 2011 Company Analysis Kolon Industries (120110) BUY (maintain) Undervalued Even in Worst-case Scenario Dongkun Kim Analyst / Hybrid Chemicals 82-2-2003-2907 dongkun.kim@hdsrc.com Daeyong
More informationSilicon Works (108320)
Earnings Review August 14, 2017 12M rating BUY (Maintain) 12M TP W50,000 from W50,000 Up/downside +44% Stock Data KOSPI (Aug 11, pt) 2,320 Stock price (Aug 11, KRW) 34,700 Market cap (USD mn) 494 Shares
More informationVITRO Conglomerates. Quarterly Report July 29, VITRO Market Outperformer 12M FWD Price Target P$73.0
Quarterly Report VITRO Market Outperformer 12M FWD Price Target P$73.0 Price 61.1 12M Price Range 36.3/ 66.7 Shares Outstanding (Mill) 483.6 Market Cap (Mill) 1,564 Float 20% Net Debt ( Mill) -424 EV Adj.
More informationLG Innotek ( KS)
(117 KS) LED earnings to improve in 4Q14 Technology Results Comment (Maintain) Buy Target Price (12M, W) 114, Share Price (1/27/14, W) 86, Expected Return 33% OP (13P, Wbn) 136 Consensus OP (13F, Wbn)
More informationEarnings to stay on growth trajectory
1 November 214 (3671 KS) Earnings to stay on growth trajectory BUY (MAINTAIN) Price (Nov 7) W1,5 Target Price W13, % variance 29.4% YoungChan Kim (82-2) 3772-1595 youngkim@shinhan.com KOSPI 1,939.87p KOSDAQ
More informationHotel Shilla ( KS)
Company Report Nov 16, 215 Hotel Shilla (877 KS) Our take on Seoul, Busan downtown duty-free license awards Retail/leisure BUY (M) TP: W153, (D) Share price (won, Nov 13) 13, Paid-in capital (Wbn) 2 Market
More informationBIMBO Food. Quarterly Report October 27, BIMBO Market Underperformer 2016 Price Target P$41.9
Quarterly Report BIMBO Market Underperformer 2016 Price Target P$41.9 Price 51.51 12M Price Range 45.02 / 59.86 Shares Outstanding (Mill) 4,703.2 Market Cap (Mill) 242,262 Float 24.0% Net Debt (Mill) 72,562
More informationPER EV/EBITDA PBR ROE
4 January 2018 (004800 KS) Valuation discount to dissipate on holdco conversion BUY (MAINTAIN) Price (Jan 3) W147,500 Target Price W180,000 % variance 22.0% Eung-Ju Lee (82-2) 3772-1559 eungju.lee@shinhan.com
More informationHyundai Wia (011210)
Hyundai Wia (011210) BUY (Reinstate), TP: W206,000 Stock price (Mar 31, KRW) 171,000 Market cap (USD mn) 4,132 Shares outstanding (mn) 26 52W High/Low (KRW) 199,500/127,000 6M avg. daily turnover (USD
More informationCEMEX Cement. Quarterly Report February 9, CEMEX remains on track to regain its investment grade.
Quarterly Report CEMEX Market Outperformer 2017 Price Target US$11.0 Price 8.9 12M Price Range 4.1/9.5 Shares Outstanding (Mill)* 1,545 Market Cap USD (Mill) 13,797 Float 78.6% Net Debt USD (Mill)** 12,516
More informationKC Tech ( KS) CMP slurry market share to increase. Display. Buy (Maintain) Raise TP by 9% to W12,000 (vs. current share price of W7,560)
March 21, 211 (2946 KS) Korea-Equity Research Display Jonathan Hwang +822-768-414 j.hwang@dwsec.com Brian Oh +822-768-4135 brian.oh@dwsec.com CMP slurry market share to increase Raise TP by 9% to W12,
More informationHyundai E&C ( KS)
Company Report (72 KS) Construction OP margin to bottom in 2Q but pick up in Q Maintain Buy call with TP of W15, We maintain our Buy call on with a target price of W15,. The company received overseas orders
More informationKolon Industries ( KS)
(1211 KS) Another beneficiary of China momentum! Korea Equity Research Chemicals Buy Maintain Buy; Raise TP to W72, We maintain our Buy call on Kolon Industries and raise our target price to W72,, from
More informationExamples = + = + = = = =
Examples = + = + = = = = Calculation of ratios an example Formula Year 1 Year 2 Year 3 Year 4 Year 5 Comments Adjusted Profit/Loss for the Period excl. Minorities 33.0 37.4 36.8 62.3 79.4 Adjusted
More informationBUY (Maintained) Tunas Baru Lampung (TBLA IJ) COMPANY UPDATE. New Raw Sugar Import Quota To Ensure Steady Performance In 2018
COMPANY UPDATE Tunas Baru Lampung (TBLA IJ) New Raw Sugar Import Quota To Ensure Steady Performance In 2018 TBLA was just allotted a 75,000-tonne raw sugar import quota. This should ensure steady inventory
More informationCOCOALAND HOLDINGS BUY. 9MFY15: On track for a record year. Company report. (Maintained) CONSUMER
CONSUMER COCOALAND HOLDINGS (COLA MK EQUITY, CCLD.KL) 26 Nov 2015 Company report Cheryl Tan, CFA cheryl-tan@ambankgroup.com 03-2036 2333 9MFY15: On track for a record year Rationale for report: Company
More informationBinggrae ( KS)
(518 KS) Operating profit to improve in 2H Food & Beverage Results Comment August 16, 213 (Maintain) Trading Buy Target Price (12M, W) 115, Share Price (8/14/13, W) 12, Expected Return 13% OP (13F, Wbn)
More informationVITRO Conglomerates. Company Note March 1, VITRO completes acquisition of the OEM Business from PGW
Company Note VITRO Market Outperformer 2017 Price Target P$88.5 Price 70.1 12M Price Range 36.3/ 66.7 Shares Outstanding (Mill) 483.1 Market Cap (Mill) 1,703 Float 20% Net Debt ( Mill) 273 EV Adj. (Mill)
More informationKOLAO Holdings ( KS)
Company Report (900140 KS) Retail New businesses need to deliver 1Q12 Review: Record earnings and stronger-than-expected margins Based on 1Q preliminary results, continued to set record earnings with revenues
More informationResetting expectations
Company update 13 May 2016 TPI ENTERPRISES (TPE) Resetting expectations We retain a BUY rating with a revised 12-month price target of $3.21 p/sh. We assess market conditions to imply a more gradual ramp
More informationYG Entertainment ( KQ)
(122870 KQ) Share issues to create near-term downside pressures Entertainment Results Comment May 19, 2014 (Maintain) Buy Target Price (12M, W) 58,000 Share Price (5/16/14, W) 48,150 Expected Return 20%
More informationTupras Keep Your Optimism
TURKEY OIL AND GAS AUGUST, 217 Tupras Common TUPRS TI Recommendation BUY Last price TRY11 Target price (from TRY19) TRY13 Upside 1% Free float 9% Market cap $,7 mln ADT, 1 days $25.2 mln Prices as of August,
More informationBuy Dec 2017 TP (IDR) 57,600 Consensus Price (IDR) 45,545 TP to Consensus Price +26.5% vs. Last Price +20.7%
Unilever Indonesia, Tbk (UNVR) Will Ads Cost Dip? Better Sales Growth UNVR booked higher sales growth since the end of 2015. The sales growth increased from 5.7% in 2015 into 9.8% in 2016, and is estimated
More informationGAIL India NEUTRAL. Performance Highlights CMP. `363 Target Price - 2QFY2013 Result Update Oil & Gas. Investment Period -
2QFY2013 Result Update Oil & Gas October 26, 2012 GAIL India Performance Highlights Quarterly highlights (Standalone) Y/E March (` cr) 2QFY2013 2QFY2012 % chg (yoy) 1QFY2013 % chg (qoq) Net sales 11,361
More informationNational Industrialization Co. Diversified Operations Industrial NIC AB: Saudi Arabia 25 May 2014
RSI10 National Industrialization Co. NIC AB: Saudi Arabia 25 May 2014 Rating Target price Current price OVERWEIGHT SAR37.30 (18.7% upside) SAR31.40 Key themes & implications Sluggish petrochemical prices
More informationAnta Sports (2020 HK)
Equity Research Consumer Discretionary Anta Sports (2020 HK) Buy (maintained) Target price: HK$18.50 Strong FY14 results; order book momentum maintained FY14 results above expectation Net profit jumped
More informationTitas Gas Transmission and Distribution Company Limited Fair Value Estimate (Dec 14) : BDT 111 per share Sector : Fuel and Power; Rating: OUTPERFORM
Dec-11 Jan-12 Feb-12 Mar-12 Apr-12 May-12 Jun-12 Jul-12 Sep-12 Sep-12 Nov-12 Dec-12 Jan-13 Jan-13 Feb-13 Apr-13 Apr-13 May-13 Jun-13 Jul-13 Sep-13 Oct-13 Nov-13 Dec-13 Jan-14 Feb-14 Price, BDT Turnover,
More informationSK Telecom ( KS)
Company Report Mar 13, 215 SK Telecom (1767 KS) Possible scenario for SK Group telecom subsidiary restructuring Telecom services BUY (M) TP: W38, (M) Share price (won, Mar 12) 27, Paid-in capital (Wbn)
More informationSamsung Market Strategy
Samsung Market Strategy 2017. 12. 27 Samsung Model Portfolio Focus to shift from seasonality to fundamentals Seung Min You Chief strategist strategist.you@ 822 2020 7024 Hyein Ok Strategist hyein.ok@ 822
More informationTrevi Group Italy Capital goods
30 August 2013 Trevi Group Italy Capital goods Buy (Hold) Target price EUR6.90 Current price EUR6.22 Matteo Bonizzoni, CFA mbonizzoni@keplercheuvreux.com +39 02 80 62 83 43 Sound delivery and business
More informationLG Innotek ( KS)
(117 KS) Future lies in automotive components Technology Company Report December 3, 215 (Maintain) Buy Target Price (12M, W) 123, Share Price (12/2/15, W) 11, Expected Return 22% OP (15F, Wbn) 241 Consensus
More informationSM Entertainment (041510)
Company Note October 21, 213 SM Entertainment (4151) 12M rating BUY (Maintain) 12M TP W54, from W54, Up/downside +45% Stock Data KOSPI (Oct 18, pt) 2,52 Stock price (Oct 18, KRW) 37,3 Market cap (USD mn)
More informationLotte Himart ( KS)
(7184 KS) Nothing left to lose Retail Earnings Preview April 6, 216 (Maintain) Buy Target Price (12M, W) 69, Share Price (4/5/16, W) 52,4 Expected Return 32% OP (16F, Wbn) 175 Consensus OP (16F, Wbn) 176
More informationBuy Dec 2018 TP (IDR) 4,770 Consensus Price (IDR) 4,002 TP to Consensus Price +19.2% vs. Last Price +61.1%
Pembangunan Perumahan Tbk (PTPP) Optimism Beyond Expectation Consistent and Stellar Growth in New Contracts Compared to other State-Owned Enterprises (SOEs) construction, PTPP s new contract growth figures
More informationSimmtech (222800) After a storm comes a calm WHAT S THE STORY?
(2228) After a storm comes a calm We initiate coverage of at BUY with a target price of KRW,. The firm was spun off from the old (now Holdings) in Jul 15. Rising utilization should boost top-line growth
More informationRajesh Exports (RJEX_IN) Earnings Update Report Consumer Discretionary: Gold Jewelry Manufacturer
Monday, February 4, 2019 www.evaluateresearch.com Target Price Rs. 900.00 Current Price Rs. 598.00 Upside Potential 50% Market Cap. Shares Outstanding Rs. 176,802 mn US$ 2.47 bn 295.3 mn Free Float (FF
More informationIOOF. Positive flows in 1Q17. FUM and Net Flows for September Qtr Source: Company data, Macquarie Research, Oct 2016.
AUSTRALIA IFL AU Price (at 06:35, 26 Oct 2016 GMT) Outperform A$8.34 Valuation A$ - DCF (WACC 8.8%, beta 1.1, ERP 5.0%, RFR 3.3%) 8.74 12-month target A$ 9.00 12-month TSR % +14.3 Volatility Index Low/Medium
More informationSemiconductor equipment
Sector Note February 18, 214 Semiconductor equipment Overweight Objective view on 3D NAND investment Company Rating TP (KRW) Eugene Technology BUY 28, Wonik IPS BUY 11,5 Semiconductor equipment shares
More informationTelkom (TLKM IJ) HOLD (from Buy) Recovery mostly priced-in. Equity Indonesia Telecommunication. Company Update. 28 November 2018
Equity Indonesia Telecommunication Telkom (TLKM IJ) HOLD (from Buy) Stock Data Target price (Rp) Prior TP (Rp) Shareprice (Rp) Rp4, Rp4,1 Rp3,72 Upside/downside (%) +7.5 Sharesoutstanding (m) 99,62 Marketcap.
More informationMRF BUY. Performance Highlights. CMP `9,407 Target Price `11,343. Company Update Automobile. Key financials
Company Update Automobile February 22, 212 MRF Performance Highlights Y/E Sept. (` cr) 1QSY12 1QSY11 % chg (yoy) 4QSY11 % chg (qoq) Net sales 2,875 2,167 32.7 2,62 9.8 EBITDA 258 243 5.9 181 42.6 EBITDA
More informationOpus Group. Equity Research. US could be supportive. Buy (Neutral) Target price: SEK 9.00 (10.0) Share price: SEK August, 2015.
Equity Research 21 August, 20 Opus Group US could be supportive Q2 EBITDA slightly better than expected US platform in place Relative pricing in favor Q2 figures The Q2 EBITDA of SEK 94m (88) was 2-3%
More informationSector Update. Pharmaceuticals(OVERWEIGHT) Short of consensus as a group; Yuhan attractive WHAT S THE STORY?
217. 7. 5 Sector Update Pharmaceuticals(OVERWEIGHT) Short of consensus as a group; Yuhan attractive We expect the combined 2Q results of the 5 largest pharmaceutical firms we cover to miss consensus, with
More informationKIMBERLY CLARK DE MEXICO Re-Rating Completed; Downgrading to Hold
Latin American Equity Research Mexico City, November 20, 2006 KIMBERLY CLARK DE MEXICO Re-Rating Completed; Downgrading to Hold Joaquín Ley* Mexico: Santander Banco Santander S.A. 5255) 5269-1921 jley@santander.com.mx
More informationSM Entertainment ( KQ)
(041510 KQ) A Chinese entertainment play Entertainment Results Comment February 18, 2016 (Maintain) Buy Target Price (12M, W) 59,000 Share Price (02/17/16, W) 38,500 Expected Return 53% OP (15F, Wbn) 36
More informationNew merchandise to prop up results
Korea/Pharmaceuticals Daewoong Pharmaceutical Earnings preview BUY 12 July 2010 BUY BUY BUY 4 May 2010 16 Apr 2010 23 Mar 2010 Ji-Won Shin, Korea Pharmaceuticals Analyst, +82 2 3774 2176 jwshin@miraeasset.com
More informationCEMEX Cement. Quarterly Report July 27, CX: Proving the success of its Value-before-Volume strategy.
Quarterly Report CEMEX Market Outperformer 12M FWD Price Target US$10.8 Price 7.1 12M Price Range 3.8/8.6 Shares Outstanding (Mill)* 1,542 Market Cap USD (Mill) 10,976 Float 78.6% Net Debt USD (Mill)**
More informationAnta Sports (2020 HK)
Equity Research Consumer Discretionary Anta Sports (2020 HK) Hold (downgraded) Target price: HK$22.80 Albert Yip, CFA SFC CE No. ADT599 albertyip@gfgroup.com.hk +852 3719 1010 GF Securities (Hong Kong)
More informationHold Dec 2018 TP (IDR) 49,450 Consensus Price (IDR) 52,798 TP to Consensus Price -6.3% vs. Last Price -8.3%
Unilever Indonesia Tbk (UNVR) Dilemma: Inclining Debt vs Declining Dividend 2017 Performance Review UNVR posted the increment of 2.9% in sales from IDR40 trillion in 2016 into IDR41.2 trillion in 2017.
More informationYansab Better than expected results
YANSAB AB: Saudi Arabia US$6.91bn 39.8% US$23.37mn Market cap Free float Avg. daily volume RSI10 Vol th Target price n/a n/a Consensus price 56.00 21.5% over current Current price 46.10 as at 9/2/2011
More informationKPN Telecom Operators - Netherlands
Exane BNP Paribas Equity Research Preview KPN Telecom Operators - Netherlands Stock vs Sector Neutral Sector vs Market Neutral Price (30 January 2007) EUR11.2 Target price 10.5 (-6%) Earnings revisions
More informationChong Kun Dang ( KS)
(185750 KS) Obesity drug beloranib to draw increasing attention Healthcare Company Update July 15, 2014 (Maintain) Buy Target Price (12M, W) 101,000 Share Price (07/14/14, W) 69,500 Expected Return 45%
More informationLuk Fook (590 HK) Hold (downgraded) Target price: HK$ HFY18 results beat, but downgrade from Accumulate to Hold on rich valuation
Equity Research Consumer Discretionary Luk Fook (590 HK) Hold (downgraded) Target price: HK$34.80 Albert Yip, CFA SFC CE No. ADT599 albertyip@gfgroup.com.hk +852 3719 1010 GF Securities (Hong Kong) Brokerage
More informationBUY Target Price, Rp 4,350 Upside 11,9%
Friday, 9 May 214 BUY Target Price, Rp 4,350 Upside 11,9% SMSM IJ/SMSM.JK Last Price, Rp 3,885 No. of shares (bn) 1,439 Market Cap, Rp bn 5,591 (US$ mn) 484 3M T/O, US$mn 0.2 Last Recommendation 09Jan14
More informationONEVIEW HEALTHCARE PLC
ONEVIEW HEALTHCARE PLC BUY 2017 Result Green Shoots Emerging Health Care Equipment & Services / Health Care Technology 28 February 2018 COMPANY UPDATE Ticker ONE Stock Price $1.900 Target Price $3.04 Forecast
More informationOur thesis considers the following:
Quarterly Report OMA Market Underperformer 2016 Price Target P$108.8 Price 114.23 12M Price Range 77.19 / 115.63 Shares Outstanding (Mill) 392.2 Market Cap (Mill) 44,796 Float 46% Net Debt (Mill) 2,782
More informationBuy Dec 2017 TP (IDR) 3,250 Consensus Price (IDR) 3,469 TP to Consensus Price -6.3% vs. Last Price +18.2%
Surya Citra Media, Tbk (SCMA) Is Optimistic about Performance Improvement Less Maximum Growth SCMA closed 2016 by booking the revenue of IDR4.5 trillion (+6.7% y-y), while in Q4 2016, SCMA s revenue was
More informationSABIC Overall strong performance
SABIC AB: Saudi Arabia US$80.80bn 22.6% US$124.7mn Market cap Free float Avg. daily volume RSI10 Vol th Target price 126.0 24.75% over current Consensus price 125.6 24.4% over current Current price 101.0
More informationSamsung Electro-Mechanics ( KS)
(009150 KS) Four reasons to buy Earnings improvement to pick up in 2Q on restructuring, Galaxy S8 launch Technology Company Update February 20, 2017 In 2017, we have been recommending that investors place
More informationCJ CGV ( KS) Strong popularity of Masquerade likely to drive 4Q earnings. Entertainment. November 1, 2012 Company Report.
Company Report (079160 KS) Entertainment Strong popularity of Masquerade likely to drive 4Q earnings Chinese and Vietnamese movie markets expected to grow rapidly According to PricewaterhouseCoopers (PwC),
More informationThailand. Earnings Results 19 ก % YoY. (02) Description :
Earnings Results Thailand 19 ก 2557 : ( ). ก ก () ก CGR Scoring Rating ( ): 25.25 ( ): 31.60 ( ) http://www.maybank-ke.co.th (02) 658-6300 ( 18 ก 2557) Description : ก ก PCB Epoxy Glass ก PCB ก ก ก กก
More information